Nedaplatin

Bezeichnung:Nedaplatin

CAS-Nr95734-82-0

Englisch Name:Nedaplatin

CBNumberCB5127746

SummenformelC2H6N2O3Pt

Molgewicht301.17

MOL-Datei95734-82-0.mol

Nedaplatin physikalisch-chemischer Eigenschaften

storage temp.	Inert atmosphere,Store in freezer, under -20°C
Löslichkeit	H2O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin's activity)DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin's activity)
Aggregatzustand	Powder
Farbe	Light yellow to yellow

Gefahreninformationscode (GHS)

Nedaplatin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.
Originator
Shionogi (Japan)
Verwenden
Nedaplatin is a platinum complex that has potent antineoplatic activity.
Verwenden
anticancer
Trademarks
Aqupla
Pharmazeutische Anwendungen
Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin. The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular, ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect is myelosuppression.

Nedaplatin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

95734-82-0, Nedaplatin Verwandte Suche:

Send Inquriy